Poietis Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 40
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $6.23M
Latest Deal Amount
  • Investors
  • 2

Poietis General Information

Description

Operator of a biotechnology company designed to specialize in the development and manufacturing of human tissues by 4D bioprinting. The company's platform develops and produces human, customized tissues using 4d bioprinting for pharmaceutical and cosmetic applications as well as develops regenerative medicine, enabling tissue engineers and researchers to get variety in the choice of biomaterials and hydrogels and enhanced versatility in their research and development.

Contact Information

Website
www.poietis.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • Bioparc Bordeaux Métropole, Building C - 1st floor
  • 27 allée Charles Darwin
  • 33600 Pessac
  • France
+33 05 00 00 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Poietis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 27-Mar-2018 $6.23M 00.000 000.00 Completed Generating Revenue
3. Later Stage VC (Series A) 14-Jan-2016 00.000 00.00 00.000 Completed Generating Revenue
2. Angel (individual) 15-Oct-2014 $178K $178K 00.000 Completed Generating Revenue
1. Accelerator/Incubator 01-Jan-2014 Completed Generating Revenue
To view Poietis’s complete valuation and funding history, request access »

Poietis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 840 $1.232613 $205.85 $205.85 1x $205.85 3.36%
To view Poietis’s complete cap table history, request access »

Poietis Patents

Poietis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3087702-B1 Isolated bio-printing device Active 25-Oct-2018 0000000000
EP-3870447-A1 Robotic bioprinting system Pending 25-Oct-2018 0000000000
FR-3087703-B1 Robotized bio-printing system Active 25-Oct-2018 0000000000
FR-3087702-A1 Isolated bio-printing device Granted 25-Oct-2018 0000000000 0
EP-3870446-A1 Enclosed bioprinting device Pending 25-Oct-2018 B29C64/364
To view Poietis’s complete patent history, request access »

Poietis Executive Team (5)

Name Title Board Seat Contact Info
Fabien Guillemot Ph.D Co-Founder, Chief Scientific Officer & Chief Executive Officer
Bertrand Viellerobe Ph.D Chief Technology Officer, Chief Innovation Officer & Board Member
Bruno Brisson Co-Founder, General Manager, Chief Business Officer & Vice President of Business Development
Dan Soto Ph.D Chief R&D Officer & Director Of Research & Development
You’re viewing 4 of 5 executive team members. Get the full list »

Poietis Board Members (1)

Name Representing Role Since
Bertrand Viellerobe Ph.D Poietis Chief Technology Officer, Chief Innovation Officer & Board Member 000 0000
To view Poietis’s complete board members history, request access »

Poietis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Poietis Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
AQUITI Gestion Venture Capital Minority 000 0000 000000 0
Incubateur Régional d'Aquitaine Accelerator/Incubator 000 0000 000000 0
To view Poietis’s complete investors history, request access »